PURPOSE: Paclitaxel is an important agent in the pharmacological treatment of metastatic breast cancer. Despite its efficacy in selected patients, the majority of patients have a resistance against paclitaxel. The aim of this study was to identify the responding patients and hence prevent the other patients from ineffective treatment. Identifying these patients could spare them an ineffective treatment and could in turn characterize a subgroup of patients with a higher response rate. MATERIAL AND METHODS: Thirty-three patients with metastatic breast cancer received paclitaxel 175 mg/m(2 )either as first- (15 patients) or as second-line (18 patients) treatment. Immunohistochemistry was performed on the blocks of the primary tumors with monoclonal antibodies against p53, HER-2/ neu, P-glycoprotein, Glutathione-S-Transferase-pi, and beta-tubulin II. The expression of those factors was then correlated with the objective response to paclitaxel. RESULTS: Ten of 33 patients had an objective response to treatment. A significant correlation with the objective response was found for the expression of p53. None of the tumors with p53 expression ( n=11) responded to paclitaxel. In contrast, 10 of the 22 patients without p53 expression showed an objective response ( P=0.013). Expression of HER-2/ neu, P-glycoprotein, Glutathione-S-Transferase-pi, and beta-tubulin II did not show a correlation with the response to paclitaxel. CONCLUSION: The immunohistochemical detection of p53 characterizes patients with metastatic breast cancer unlikely to respond to paclitaxel.
PURPOSE:Paclitaxel is an important agent in the pharmacological treatment of metastatic breast cancer. Despite its efficacy in selected patients, the majority of patients have a resistance against paclitaxel. The aim of this study was to identify the responding patients and hence prevent the other patients from ineffective treatment. Identifying these patients could spare them an ineffective treatment and could in turn characterize a subgroup of patients with a higher response rate. MATERIAL AND METHODS: Thirty-three patients with metastatic breast cancer received paclitaxel 175 mg/m(2 )either as first- (15 patients) or as second-line (18 patients) treatment. Immunohistochemistry was performed on the blocks of the primary tumors with monoclonal antibodies against p53, HER-2/ neu, P-glycoprotein, Glutathione-S-Transferase-pi, and beta-tubulin II. The expression of those factors was then correlated with the objective response to paclitaxel. RESULTS: Ten of 33 patients had an objective response to treatment. A significant correlation with the objective response was found for the expression of p53. None of the tumors with p53 expression ( n=11) responded to paclitaxel. In contrast, 10 of the 22 patients without p53 expression showed an objective response ( P=0.013). Expression of HER-2/ neu, P-glycoprotein, Glutathione-S-Transferase-pi, and beta-tubulin II did not show a correlation with the response to paclitaxel. CONCLUSION: The immunohistochemical detection of p53 characterizes patients with metastatic breast cancer unlikely to respond to paclitaxel.
Authors: A Chadderton; D J Villeneuve; S Gluck; A F Kirwan-Rhude; B R Gannon; D E Blais; A M Parissenti Journal: Breast Cancer Res Treat Date: 2000-02 Impact factor: 4.872
Authors: H Shiga; E I Heath; A A Rasmussen; B Trock; P G Johnston; A A Forastiere; M Langmacher; A Baylor; M Lee; K J Cullen Journal: Clin Cancer Res Date: 1999-12 Impact factor: 12.531
Authors: M Michael; J F Bishop; J A Levi; D R Bell; J R Zalcberg; M L Friedlander; I N Olver; J G Smith; G C Toner Journal: Med J Aust Date: 1997-05-19 Impact factor: 7.738
Authors: X Yang; B Uziely; S Groshen; J Lukas; V Israel; C Russell; G Dunnington; S Formenti; F Muggia; M F Press Journal: Lab Invest Date: 1999-03 Impact factor: 5.662
Authors: S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks Journal: Science Date: 1994-11-04 Impact factor: 47.728
Authors: Daniel Pretto Schunemann; Ivana Grivicich; Andréa Regner; Lisiane Freitas Leal; Daniela Romani de Araújo; Geraldo Pereira Jotz; Carlos Alexandre Fedrigo; Daniel Simon; Adriana Brondani da Rocha Journal: Pathol Oncol Res Date: 2009-12-08 Impact factor: 3.201
Authors: Flora Doffe; Vincent Carbonnier; Manon Tissier; Bernard Leroy; Isabelle Martins; Johanna S M Mattsson; Patrick Micke; Sarka Pavlova; Sarka Pospisilova; Jana Smardova; Andreas C Joerger; Klas G Wiman; Guido Kroemer; Thierry Soussi Journal: Cell Death Differ Date: 2020-11-30 Impact factor: 15.828
Authors: Carlos A Fedrigo; Ivana Grivicich; Daniel P Schunemann; Ivan M Chemale; Daiane dos Santos; Thais Jacovas; Patryck S Boschetti; Geraldo P Jotz; Aroldo Braga Filho; Adriana B da Rocha Journal: Radiat Oncol Date: 2011-11-11 Impact factor: 3.481
Authors: Marcus Schmidt; Barbara Lewark; Nikolai Kohlschmidt; Christiane Glawatz; Erik Steiner; Berno Tanner; Henryk Pilch; Wolfgang Weikel; Heinz Kölbl; Hans-Anton Lehr Journal: Breast Cancer Res Date: 2005-01-26 Impact factor: 6.466